Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Blueprint Medicines Community
NasdaqGS:BPMC Community
1
Narratives
written by author
0
Comments
on narratives written by author
14
Fair Values set
on narratives written by author
Create a narrative
Blueprint Medicines
Popular
Undervalued
Overvalued
Community Investing Ideas
Blueprint Medicines
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
Expanding Patient Reach And Pipeline Development Will Unlock Potential
Key Takeaways Strong AYVAKIT demand, expanded market reach, and improved therapy duration fuel revenue growth and enhance operating margin stability. Diversified pipeline, efficient cost structure, and international expansion reduce reliance on a single product and support long-term earnings growth.
View narrative
US$125.90
FV
24.3% undervalued
intrinsic discount
30.24%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
about 9 hours ago
author updated this narrative
Your Valuation for
BPMC
BPMC
Blueprint Medicines
Your Fair Value
US$
Current Price
US$95.30
19.6% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-650m
1b
2015
2018
2021
2024
2025
2027
2030
Revenue US$1.5b
Earnings US$286.0m
Advanced
Set Fair Value